# ClinicalTrials.gov record NCT05646706

> PeptideScanner retained ClinicalTrials.gov record NCT05646706 at 2026-07-30T16:20:49.307Z. Its registry update date was 2026-04-23, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct05646706-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05646706-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct05646706-semaglutide-v1.json
- Content SHA-256: `90926a7f6bdfd90a7f5220b256d81a49aeb684a17e301668ee601155d393d9c4`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT05646706 ([`ctg-observation-nct05646706-2026-04-23-229db4f2c6e8`](#source-ctg-observation-nct05646706-2026-04-23-229db4f2c6e8))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05646706 at 2026-07-30T16:20:49.307Z. Its registry update date was 2026-04-23, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05646706-2026-04-23-229db4f2c6e8`](#source-ctg-observation-nct05646706-2026-04-23-229db4f2c6e8))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05646706 at 2026-07-30T16:20:49.307Z. Its registry update date was 2026-04-23, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05646706-2026-04-23-229db4f2c6e8`](#source-ctg-observation-nct05646706-2026-04-23-229db4f2c6e8))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05646706-2026-04-23-229db4f2c6e8`](#source-ctg-observation-nct05646706-2026-04-23-229db4f2c6e8))

## Sources

<a id="source-ctg-observation-nct05646706-2026-04-23-229db4f2c6e8"></a>
- **ClinicalTrials.gov record NCT05646706 · retained source version 2026-04-23:229db4f2c6e8efc3c7c6a3d8a5979869a1a41421cb1d9f77057e92089305f143** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05646706) (`ctg-observation-nct05646706-2026-04-23-229db4f2c6e8`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05646706." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct05646706-semaglutide-v1.json SHA-256: 90926a7f6bdfd90a7f5220b256d81a49aeb684a17e301668ee601155d393d9c4.